IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35766165/
IMPROVE bleeding score may predict the risk for bleeding in gastrointestinal cancer patients with venous thromboembolism. Selecting patients with a low risk of bleeding using with IMPROVE bleeding score is...
Conclusions: IMPROVE bleeding score may predict the risk for bleeding in gastrointestinal cancer patients with venous thromboembolism. Selecting patients with a low risk of bleeding using with IMPROVE bleeding score is expected to contribute to the safer management of anticoagulation therapy for cancer-associated thromboembolism.
Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34712676/
doi: 10.3389/fmed.2021.719236. 1 Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 2 Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China....
Conclusions: Cholestatic hepatitis is a rarely reported toxicity of immune checkpoint inhibitors, which should be suspected and addressed once obstructive jaundice is ruled out. In addition, clinicians should be aware that irAEs can occur at any time in patients treated with immune checkpoint inhibitors and that a timely diagnosis should be...
Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).
Source : https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.217
217 Background: Ramucirumab (RAM) is a fully human IgG1 monoclonal vascular endothelial growth factor receptor-2 (VEGFR-2) antibody. The RAINBOW trial showed RAM plus paclitaxel (PTX) increased overall survival (OS) compared...
Conclusion: Although the primary endpoint was not achieved statistically, combination therapy of ramucirumab plus irinotecan showed anticancer activity and a manageable safety profile for second-line treatment of patients with advanced gastric cancer.
The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data
Source : https://www.futuremedicine.com/doi/10.2217/fon-2022-0281
Despite the availability of multiple treatment options, the prognosis for advanced gastric cancer (AGC) remains poor and more effective treatment options are needed. Ramucirumab is an established and recommended second-line...
Conclusion/Relevance: Currently, ramucirumab is the only approved anti-angiogenic therapy for AGC in the majority of countries worldwide, and interest in ramucirumab remains strong. Since 2014, many studies have been conducted on ramucirumab in combination with new therapeutics with various mechanisms of action and in new clinical settings to...
Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report - World Journal of Surgical Oncology
Source : https://wjso.biomedcentral.com/articles/10.1186/s12957-022-02661-8
Background Immune checkpoint inhibitors are reportedly effective in treating microsatellite instability (MSI)-high gastric cancer. There are a few case reports of conversion surgery (CS) with nivolumab but none with pembrolizumab....
Conclusions: Conversion surgery following pembrolizumab monotherapy has a potential utility for the treatment of MSI-high gastric cancer.